NBIO (NBIO) Stock Price & Analysis
NBIO (NBIO) rose 0.00% to USD 0 as of July 25, 2026 at 14:26 UTC, according to Nexqual real-time market data.
NBIO last closed at USD 0; the session ranged USD 0–0 on volume of 15,000 shares. Market capitalization is $103,330, with a 52-week range of USD 0–0.13 (PNK). Source: Nexqual, July 25, 2026 at 14:26 UTC.
Key Statistics (as of July 25, 2026 at 14:26 UTC)
| Price | USD 0 |
|---|---|
| Change | ▲ 0.00% (up) |
| Previous Close | USD 0 |
| Open | USD 0 |
| Day Range | USD 0 – 0 |
| 52-Week Range | USD 0 – 0.13 |
| Volume | 15,000 shares |
| Market Cap | $103,330 |
| Exchange | PNK |
Technical Analysis (NBIO)
Nexqual's technical model rates NBIO "NEUTRAL" based on 3 bullish and 2 bearish signals across 125 daily candles, as of July 25, 2026 at 14:26 UTC.
| Overall Signal | NEUTRAL |
|---|---|
| RSI (14) | 56.28 (neutral) |
| vs SMA50 | Below (USD 0) |
| MACD | 0 (negative) |
Analyst Ratings (NBIO)
Wall Street analysts rate NBIO "None", per Nexqual as of July 25, 2026 at 14:26 UTC.
| Consensus Rating | None |
|---|
Earnings (NBIO)
Source: Nexqual, July 25, 2026 at 14:26 UTC.
Financials & Fundamentals (NBIO)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| Current Ratio | 0.31 |
| Total Cash | $47,391 |
| Total Debt | $59,000 |
| Free Cash Flow | $-825,141 |
Source: Nexqual, July 25, 2026 at 14:26 UTC.
Financial Health Score (NBIO)
Nexqual rates NBIO's overall financial health "Weak" across five dimensions, as of July 25, 2026 at 14:26 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Gross margin 0%, operating 0% |
| Balance Sheet | Mixed — $47K cash, no debt |
| Cash Flow | Weak — Operating cash flow -$1M |
| Efficiency | Mixed — No data |
Ownership (NBIO)
| Insider Ownership | +21.51% |
|---|---|
| Institutional Ownership | +0.00% |
| Shares Outstanding | 172.22M |
| Float | 135.39M |
Source: Nexqual, July 25, 2026 at 14:26 UTC.
Leadership (NBIO)
NBIO is led by Sean Carrick (age 57), President, CEO, Secretary & Director, per Nexqual as of July 25, 2026 at 14:26 UTC.
| President, CEO, Secretary & Director | Sean Carrick (age 57) |
|---|---|
| CFO, Chief Accounting Officer & Director | Lowell Holden (age 82) |
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| SRBCF | Sirona Biochem Corp. | USD 0.01 | ▲ 0% |
| RASP | ACTAVIA LIFE SCIENCES INC | USD 0 | ▲ 0% |
| KNBIF | Kane Biotech Inc. | USD 0.02 | ▲ 0% |
| PKTX | ProtoKinetix, Inc. | USD 0.01 | ▲ 3.12% |
| BEGI | BlackStar Enterprise Group, Inc | USD 0 | ▲ 0% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 14:26 UTC. This page is informational and not investment advice.